Дистрофическая минерализация мягких тканей: параллели в формировании дисфункций биопротезов клапанов сердца, кальцинированного аортального стеноза и атеросклероза

DOI: https://dx.doi.org/10.18565/cardio.2015.8.76-85

Рутковская Н.В., Барбараш О.Л.

ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, Кемерово
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  1. Tillquist M., Maddox T. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Preference and Adherence 2011;5:91–99.
  2. Schoen F.J., Levy R.J., Piehler H.R. Pathological considerations in replacement heart valves. Cardiovascular pathology 1992;1:29–52.
  3. O’Keefe J.H., Lavie C.J., Nishimura R.A., Edwards W.D. Degenerative aortic stenosis. Postgrad Med 1991;89:143–154.
  4. Pibarot P., Dumesnil J. Prosthetic Heart Valves: Selection of the Optimal Prosthesis and Long-Term Management. Circulation 2009;119:1034–1048.
  5. Oakley R., Kleine P., Bach D.S. Choice of Prosthetic Heart Valve in Today's Practice. Circulation 2008;117:253–256.
  6. Jamieson W.R., Cartier P.C., Allard M. Surgical management of valvular heart disease. Canadian Journal of Cardiology 2004;20(suppl E):7E–120E.
  7. Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Annals of Thoracic Surgery 2005;79:1072–1080.
  8. Rahimtoola S.H. Choice of prosthetic heart valve for adult patients. Journal of the American College of Cardiology 2003;41:893–904.
  9. Van Geldorp M., Jamieson E., Kappetein A.P. Ye J., Fradet G.J., Eijkemans M.J., Grunkemeier G.L., Bogers A.J., Takkenberg J.J. Patient outcome after aortic valve replacement with a mechanical
  10. or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. Journal of Thoracic and Cardiovascular Surgery 2009;137:881–886.
  11. Barbarash L.S., Zhuravleva I.Y. The evolution of heart valve bioprosthesis: Achievements and Challenges two decades. Complex problems of cardiovascular disease 2012;1:4–11. Russian (Барбараш Л.С., Журавлева И.Ю. Эволюция биопротезов клапанов сердца: достижения и проблемы двух десятилетий. Комплексные проблемы сердечно-сосудистых заболеваний 2012;1: 4–11).
  12. Schoen F.J., Harasaki H., Kim K.M., Anderson H.C., Levy R.J. Biomaterial associated calcification: pathology, mechanisms, and strategies for prevention. Journal of Biomedical Materials Research 1988;22 (Suppl. A1):11–36.
  13. Schoen F.J., Kujovitch J., Levy R.J., Sutton M.S. Bioprosthetic valve failure. Cardiovascular clinics 1988;18:289–317.
  14. Schoen F.J. Cardiac valve prostheses: review of clinical status and contemporary biomaterials issues. Journal of Biomedical Materials Research 1987;21(Suppl. A1):91–117.
  15. Pernmanyer-Miralda G., Soler-Soler J., Casan-Cava J.M., Tornos-Mas M.P. Medium term fate of dura mater valvular bioprostheses. European Heart Journal 1980;1:195–199.
  16. Allen D.J., Highison G.J., Didio L.J., Zerbini E.J., Puig L.B. Evidence of remodeling in dura mater cardiac valves. Journal of Thoracic and Cardiovascular Surgery 1982;84:267–281.
  17. Schoen F.J. Cardiac valve prostheses. Pathologic and bioengineering considerations. Journal of Cardiovascular Surgery 1987;2:65–108.
  18. Hilbert S.L., Ferrans V.J., Tomita Y., Eidbo E. E., Jones M. Evaluation of explanted polyurethane trileaflet cardiac valve prostheses. Journal of Thoracic and Cardiovascular Surgery 1987;94:419–429.
  19. Harasaki H., McMahon J., Richards T., Goldcamp J., Kiraly R., Nose Y. Calcification in cardiovascular implants: degraded cell related phenomena. Transactions – American Society for Artificial Internal Organs 1985;31:489–494.
  20. Srivatsa S.S., Harrity P.J., Maercklein P.B., Maercklein P.B., Kleppe L., Veinot J. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. Journal of Clinical Investigation 1997;99:996–1009.
  21. Briand M., Pibarot P., Despres J.P., Voisine P., Dumesnil J.G., Dagenais F., Mathieu P. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006;114:1512–1517.
  22. Mahjoub Y., Mathieu P., Senechal M., Larose E., Dumesnil J., Després J.P., Pibarot P. ApoB/ApoA ratio is associated with increased risk bioprosthetic valve degeneration. Journal of the American College of Cardiology 2013;61:752–761.
  23. Nollert G., Miksch J., Kreuzer E., Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery 2003;126:965–968.
  24. Farivar R.S., Cohn L.H. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. Journal of Thoracic and Cardiovascular Surgery 2003;126:969–975.
  25. Levy R.J., Schoen F.J., Levy J.T., Nelson A.C., Howard S.L., Oshry L.J. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde preserved porcine aortic valve leaflets implanted subcutaneously in rats. American Journal of Pathology 1983;113:143–155.
  26. Togashi M., Tamura K., Masuda Y., Fukuda Y. Comparative study of calcified changes in aortic valvular diseases. Journal of Nippon Medical School 2008;75:138–145.
  27. Waggett A.D., Kielty C.M., Shuttleworth C.A. Microfibrillar elements in the synovial joint: presence of type IV collagen and fibrillin – containing microfibrils. Annals of the Rheumatic Diseases 1993;52: 449–453.
  28. Daamen W.F., Nillesen S.T., Hafmans T., Veerkamp J.H., Luyn M.J., Kuppevelt T.H. Tissue response of defined collagen-elastin scaffolds in young and adult rats with special attention of calcification. Biomaterials 2005;26:81–92.
  29. Schoen F.J., Levy R.J. Tissue heart valves: current challenges and future research perspectives. Journal of Biomedical Materials Research 1999;47:439–65.
  30. Schoen F.J., Tsao J.W., Levy R.J. Calcification of bovine pericardium used in cardiac valve bioprostheses. Implications for mechanisms of bioprosthetic tissue mineralization. American Journal of Pathology 1986;23:143–54.
  31. Schoen F.J. Future directions in tissue heart valves: impact of recent insights from biology and pathology. The Journal of heart valve disease 1999;8:350–358.
  32. Bailey M.T., Pillarisetti S., Xiao H., Vyavahare N.R. Role of elastin in pathologic calcification of xenograft heart valves. Journal of Biomedical Materials Research 2003;66:93–102.
  33. Miller J.D., Weiss R.M., Heistad D.D. Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms. Circulation Research 2011;108:1392–1412.
  34. Hjortnaes J., Butcher J., Figueiredo J.L., Riccio M., Kohler R.H., Kozloff K.M., Weissleder R., Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. European Heart Journal 2010;31:1975–1984.
  35. Aronow W.S. Osteoporosis, osteopenia, and atherosclerotic vascular disease. Archives of Medical Science 2011;7:21–26.
  36. New S.E.P., Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circulation Research 2011;108:1381–1391.
  37. Aikawa E., Nahrendorf M., Sosnovik D., Lok V.M., Jaffer F.A., Aikawa M., Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007;115:377–386.
  38. Aikawa E., Nahrendorf M., Figueiredo J.L., Swirski F.K., Shtatland T., Kohler R.H., Jaffer F.A., Aikawa M., Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007;116:2841–2850.
  39. Peacock J.D., Levay A.K., Gillaspie D.B., Tao G., Lincoln J. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circulation Research 2010;106:712–719.
  40. El-Abbadi M., Giachelli C.M. Mechanisms of vascular calcification. Advances in Chronic Kidney Disease 2007;14:54–66.
  41. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522–1528.
  42. Vattikuti R., Towler D.A. Osteogenic regulation of vascular calcification: an early perspective. Endocrinology and Metabolism – American Journal of Physiology 2004;286:E686–E696.
  43. Kalantari F., Miao D., Emadali A., Tzimas G.N., Goltzman D., Vali H., Chevet E., Auguste P. Cellular and molecular mechanisms of abnormal calcification following ischemia–reperfusion injury in human liver transplantation. Modern Pathology 2007;20:357–366.
  44. Huh C.G., Factor V.M., Sanchez A., Uchida K., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proceedings of the National Academy of Sciences USA 2004;101:4477–4482.
  45. O'Neill W.C. The fallacy of the calcium-phosphorus product. Kidney International 2007;72:792–796.
  46. Ketteler M., Schlieper G., Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006;47:1027–1034.
  47. Block G.A., Spiegel D.M., Ehrlich J., Mehta R., Lindbergh J., Dreisbach A., Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International 2005;68:1815–1824.
  48. Oh J., Wunsch R., Turzer M., Bahner M., Raggi P., Querfeld U., Mehls O., Schaefer F. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100–105.
  49. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., Morii H., Giachelli C.M. Phosphate regulation of vascular smooth muscle cell calcification. Circulation Research 2000;87:E10–E17.
  50. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., Schurgers L.J., Proudfoot D., Jahnen-Dechent W., Weissberg P.L., Shanahan C.M. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. Journal of the American Society of Nephrology 2004;15:2857–2867.
  51. Mody N., Parhami F., Sarafian T.A., Demer L.L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Journal of Free Radicals in Biology and Medicine 2001;31:509–519.
  52. Miller J.D., Weiss R.M., Serrano K.M., Brooks R.M., Berry C.J., Zimmerman K., Young S.G., Heistad D.D. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009;119:2693–2701.
  53. Miller J.D., Weiss R.M., Serrano K.M., Castaneda, L.E., Brooks R.M., Zimmerman K., Heistad D.D. Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arteriosclerosis, Thrombosis and Vascular Biology 2010;30:2482–2486.
  54. Rajamannan N.M., Nealis T.B., Subramaniam M., Pandya S., Stock S.R., Ignatiev C.I., Sebo T.J., Rosengart T.K., Edwards W.D., McCarthy P.M., Bonow R.O., Spelsberg T.C. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005;111:3296–3301.
  55. Wylie-Sears J., Aikawa E., Levine R.A., Yang J.H., Bischoff J. Mitral valve endothelial cells with osteogenic differentiation potential. Arteriosclerosis, Thrombosis and Vascular Biology 2011;31:598–607.
  56. Paranya G., Vineberg S., Dvorin E., Kaushal S., Roth S.J., Rabkin E., Schoen F.J., Bischoff J. Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. American Journal of Pathology 2001;159:1335–1343.
  57. Eghbali-Fatourechi G.Z., Modder U.I., Charatcharoenwitthaya N., Sanyal A., Undale A.H., Clowes J.A., Tarara J.E., Khosla S. Characterization of circulating osteoblast lineage cells in humans. Bone 2007;40:1370–1377.
  58. Khosla S., Eghbali-Fatourechi G.Z. Circulating cells with osteogenic potential. Annals of the New York Academy of Sciences 2006;1068:489–497.
  59. Olmsted-Davis E.A., Gugala Z., Camargo F., Gannon F.H., Jackson K., Kienstra K.A., Shine H.D., Lindsey R.W., Hirschi K.K., Goodell M.A., Brenner M.K., Davis A.R. Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proceedings of the National Academy of Sciences USA 2003;100:15877–15882.
  60. Chen J.H., Simmons C.A. Cell–matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circulation Research 2011;108:1510–1524.
  61. Steiner I., Kasparová P., Kohout A., Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Archiv 2007;450:653–657.
  62. Visconti R.P., Ebihara Y., LaRue A.C., Fleming P.A., McQuinn T.C., Masuya M., Minamiguchi H., Markwald R.R., Ogawa M., Drake C.J. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circulation Research 2006;98:690–696.
  63. Deb A., Wang S.H., Skelding K., Miller D., Simper D., Caplice N. Bone marrow-derived myofibroblasts are present in adult human heart valves. Journal of Heart Valve Disease 2005;14:674–678.
  64. Huebsch N., Arany P.R., Mao A.S., Shvartsman D., Ali O.A., Bencherif S.A., Rivera-Feliciano J., Mooney D.J. Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate. Nature materials 2010;9:518–526.
  65. Bottio T., Thiene G., Pettenazzo E., Ius P., Bortolotti U., Rizzoli G., Valfré C., Casarotto D., Valente M. Hancock II bioprosthesis: a glance at the microscope in mid-long-term explants. Journal of Thoracic and Cardiovascular Surgery 2003;126:99–105.
  66. Honge J.L, Funder J.A., Pedersen T.B., Kronborg M.B., Hasenkam J.M., Degenerative processes in bioprosthetic mitral valves in juvenile pigs. Journal of Cardiothoracic Surgery 2011;6:72.
  67. Duer M.J., Friscic T., Proudfoot D., Reid D.G., Schoppet M., Shanahan C.M., Skepper J.N., Wise E.R. Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arteriosclerosis, Thrombosis and Vascular Biology 2008;28:2030–2034.
  68. Speer M.Y., Giachelli C.M. Regulation of vascular calcification. Cardiovascular Pathology 2004;13:63–70.
  69. Wirrig E.E., Hinton R.B., Yutzey K.E. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. Journal of Molecular and Cellular Cardiology 2011;50:561–569.
  70. Sucosky P., Balachandran K., Elhammali A., Jo H., Yoganathan A.P. Altered shear stress stimulates upregulation of endothelial vcam-1 and icam-1 in a bmp-4- and tgf-beta1-dependent pathway. Arteriosclerosis, Thrombosis and Vascular Biology 2009;29:254–260.
  71. Benton J.A., Kern H.B., Anseth K.S. Substrate properties influence calcification in valvular interstitial cell culture. The Journal of Heart Valve Disease 2008;17:689–699.
  72. Kennedy J.A., Hua X., Mishra K., Murphy G.A., Rosenkranz A.C., Horowitz J.D. Inhibition of calcifying nodule formation in cultured porcine aortic valve cells by nitric oxide donors. European Journal of Pharmacology 2009;602:28–35.
  73. Clark-Greuel J.N., Connolly J.M., Sorichillo E., Narula N.R., Rapoport H.S., Mohler E.R., Gorman J.H., Gorman R.C., Levy R.J. Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. The Annals of Thoracic Surgery 2007;83:946–953.
  74. Cushing M.C., Liao J.T., Anseth K.S. Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. Matrix Biology 2005;24:428–437.
  75. Chen J.H., Chen W.L., Sider K.L., Yip C.Y., Simmons C.A. {beta}-catenin mediates mechanically regulated, transforming growth factor-{beta}1-induced myofibroblast differentiation of aortic valve interstitial cells. Arteriosclerosis, Thrombosis and Vascular Biology 2011;31:590–597.
  76. Shimizu T., Tanaka T., Iso T., Doi H., Sato H., Kawai-Kowase K., Arai M., Kurabayashi M. Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: role of msx2 gene induction via notch-rbp-jk signaling. Arteriosclerosis, Thrombosis and Vascular Biology 2009;29:1104–1111.
  77. Gu X., Masters K.S. Role of the MAPK/ERK pathway in valvular interstitial cell calcification. American Journal of Physiology 2009; 296:H1748–H1757.
  78. D'Amelio P., Isaia G., Isaia G.C. The osteoprotegerin/rank/rankl system: a bone key to vascular disease. Journal of Endocrinological Investigation 2009;32:6–9.
  79. Boyce B.F., Xing L. Biology of rank, rankl, and osteoprotegerin. Arthritis Research and Therapy 2007;9:S1.
  80. Byon C.H., Sun Y., Chen J., Yuan K., Mao X., Heath J.M., Anderson P.G., Tintut Y., Demer L.L., Wang D., Chen Y. Runx2-upregulated receptor activator of nuclear factor {kappa}b ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arteriosclerosis, Thrombosis and Vascular Biology 2011;31:1387–1396.
  81. Wada T., McKee M. D., Steitz S., Giachelli C.M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circulation Research 1999;84:166–178.
  82. Steitz S.A., Speer M.Y., McKee M.D. Liaw L., Almeida M., Yang H., Giachelli C.M. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. American Journal of Pathology 2002;161:2035–2046.
  83. Ingram, R.T., Clarke B.T., Fisher L.W., Fitzpatrick L.A. Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity. Journal of Bone and Mineral Research 1993;8:1019–1029.
  84. Parhami F., Basseri B., Hwang J., Tintut Y., Demer L.L. High-density lipoprotein regulates calcification of vascular cells. Circulation Research 2002;91:570–576.
  85. Schinke T., McKee M.D., Karsenty G. Extracellular matrix calcification: where is the action? Nature Genetics 1999;21:150–151.
  86. Demer L.L. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. International Journal of Epidemiology 2002;31:737–41.
  87. New S.E., Aikawa E. Cardiovascular сalcification an inflammatory disease. Circulation Journal 2011;75:1305–1313.
  88. Demer L.L., Tintut Y. Mechanisms linking osteoporosis with cardiovascular calcification. Current Osteoporosis Reports Journal 2009;7:42–46.
  89. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004;109(Suppl. II):II2–10.
  90. Demer L.L., Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008;117:2938–2948.
  91. Demer L.L., Tintut Y. Return to ectopia: stem cells in the artery wall. Arteriosclerosis, Thrombosis and Vascular Biology 2005;25:1307–1308.
  92. Yu Z., Seya K., Daitoku K., Motomura S., Fukuda I., Furukawa K. Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. Journal of Pharmacology and Experimental Therapeutics 2011;337:16–23.
  93. Freeman R.V., Otto C.M. Spectrum of calcific aortic valve disease, pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316–3326.
  94. Jian B., Narula N., Li Q.Y., Mohler E.R., Levy R.J. Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. The Annals of Thoracic Surgery 2003;75:457–466.
  95. Kaden J.J., Dempfle C.E., Grobholz R., Tran H.T., Kiliс R., Sarikoс A., Brueckmann M., Vahl C., Hagl S., Haase K.K., Borggrefe M. Interleukin-1β promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003;170:205–211.
  96. Wallby L., Janerot-Sjöberg B., Steffensen T., Broqvist M. T-lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002;88:348–351.
  97. Isoda K., Matsuki T., Kondo H., Iwakura Y., Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in balb/c mice. Arteriosclerosis, Thrombosis and Vascular Biology 2010;30:708–715.
  98. Al-Aly Z., Shao J.S., Lai C.F., Huang E., Cai J., Behrmann A., Cheng S.L., Towler D.A. Aortic msx2-wnt calcification cascade is regulated by tnf-alpha-dependent signals in diabetic ldlr−/− mice. Arteriosclerosis, Thrombosis and Vascular Biology 2007;27:2589–2596.
  99. Hamid T., Gu Y., Ortines R.V., Bhattacharya C., Wang G., Xuan Y.T., Prabhu S.D. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappab and inflammatory activation. Circulation 2009;119:1386–1397.
  100. Bradley J.R. TNF-mediated inflammatory disease. The Journal of Pathology 2008;214:149–160.
  101. Hess K., Ushmorov A., Fiedler J., Brennerb R.E., Wirth T. TNFα promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-κB signaling pathway. Bone 2009;45:367–376.
  102. Wu S., Flint J.K., Rezvani G., De Luca F. Nuclear factor-κB p65 facilitates longitudinal bone growth by inducing growth plate chondrocyte proliferation and differentiation and by preventing apoptosis. Journal of Biological Chemistry 2007;282:33698–33706.
  103. Alexandraki K., Piperi C., Kalofoutis C., Singh J., Alaveras A., Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Annals of the New York Academy of Sciences 2006;1084:89–117.
  104. Guzik T.J., Mangalat D., Korbut R. Adipocytokines – novel link between inflammation and vascular function? Journal of physiology and pharmacology 2006;57:505–528.
  105. Cote C., Pibarot P., Despres J.P., Mohty D., Cartier A., Arsenault B.J., Couture C., Mathieu P. Association between circulating oxidized low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175–1180.
  106. Shetty R., Pibarot P., Auget A., Janvier R., Dagenais F., Perron J., Couture C., Voisine P., Desprеs J.P., Mathieu P. Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. European Journal of Clinical Investigation 2009;39:471–480.
  107. Shetty R., Pibarot P., Charest A., Janvier R., Dagenais F., Perron J., Couture C., Voisine P., Desprеs J.P., Mathieu P. Implication of lipid-mediated inflammation in the structural degeneration of bioprosthetic heart values. European Journal of Clinical Investigation. Rajamannan N.M., Arterburn L., Bares R., Flores A., Caira F. Atorvastatin attenuates bioprosthetic heart valve calcification in a rabbit model via a stem cell mediated mechanism. Journal of the American College of Cardiology 2008;51(Suppl. A):277.
  108. Antonii-Canterin F., Zuppiroli A., Baldessin F., Popescu B.A., Nicolosi G.L. Is there a role of statins in the prevention of aortic biological prostheses degeneration. Cardiovascular Ultrasound 2006; 4:26.
  109. Parolari A., Tremoli E., Cavallotti L., Trezzi M., Kassem S., Loardi C., Veglia F., Ferrari G., Pacini D., Alamanni F. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 2011;97:523–529.
  110. Holme I., Boman K., Brudi P., Egstrup K., Gohlke-Baerwolf C., Kesаniemi Y.A., Malbecq W., Rossebо A.B., Wachtell K., Willenheimer R., Pedersen T.R. Observed and predictedreduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial. American Journal of Cardiology 2010;105:1802–1808.
  111. Bellamy M. F., Pellica P.А., Klrish K.W., Tajik A.J., Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. Journal of the American College of Cardiology 2002;40:1723–1730.
  112. Tanaka K., Sata M., Fukuda D., Suematsu Y., Motomura N., Takamoto S., Hirata Y., Nagai R. Age-associated aortic stenosis in apolipoprotein E-deficient mice. Journal of the American College of Cardiology 2005;46(1):134–141.
  113. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual–purpose therapies. Quarterly journal of medicine 2005;98:467–484.
  114. Muller A.M., Cronen C., Kupferwasser L, Oelert H., Muller K.M., Kirkpatrick C.J. Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. Journal оf Pathology 2000;191:54–60.
  115. Ghaisas N.K., Foley J.B., O'Briain D.S., Crean P., Kelleher D., Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. Journal of the American College of Cardiology 2000;36:2257–2262.
  116. Rabkin E., Hoerstrup S.P., Aikawa M., Mayer J.E., Schoen F.J. Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling. Journal оf Heart Valve Disease 2002;11:308–314.
  117. Rabkin-Aikawa E., Farber M., Aikawa M., Schoen F.J. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. Journal оf Heart Valve Disease 2004;13:841–847.
  118. Deguchi J.O., Aikawa E., Libby P., Vachon J.R., Inada M., Krane S.M., Whittaker P., Aikawa M. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005;112:2708–2715.
  119. Helske S., Syvaranta S., Lindstedt K.A., Lappalainen J., Oörni K., Mäyränpää M.I., Lommi J., Turto H., Werkkala K., Kupari M., Kovanen P.T. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arteriosclerosis, Thrombosis and Vascular Biology 2006;26:1791–1798.
  120. Balachandran K., Sucosky P., Yoganathan A.P. Hemodynamics and mechanobiology of aortic valve inflammation and calcification. International Journal of Inflammation 2011; 2011: 263870.
  121. Chaput M., Handschumacher M.D., Tournoux F., Hua L., Guerrero J.L., Vlahakes G.J., Levine R.A. Mitral leaflet adaptation to ventricular remodeling occurrence and adequacy in patients with functional mitral regurgitation. Circulation 2008;118:845–852.
  122. Dal-Bianco J.P., Aikawa E., Bischoff J., Guerrero J.L., Handschumacher M.D., Sullivan S., Johnson B., Titus J.S., Iwamoto Y., Wylie-Sears J., Levine R.A., Carpentier A. Active adaptation of the tethered mitral valve: insights into a compensatory mechanism for functional mitral regurgitation. Circulation 2009;120:334–342.
  123. Simmons C.A., Grant G.R., Manduchi E., Davies P.F. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circulation Research 2005;96:792–799.
  124. Butcher J.T., Penrod A.M., García A.J., Nerem R.M. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arteriosclerosis, Thrombosis and Vascular Biology 2004;24:1429–1434.
  125. Butcher J.T., Simmons C.A., Warnock J.N. Mechanobiology of the aortic heart valve. Journal of Heart Valve Disease 2008; 17: 62–73.
  126. Taylor P.M., Batten P., Brand N.J., Thomas P.S., Yacoub M.H. The cardiac valve interstitial cell. International Journal of Biochemistry and Cell Biology 2003;35:113–118.
  127. Durbin A.D., Gotlieb A.I. Advances towards understanding heart valve response to injury. Cardiovascular Pathology 2002;11:69–77.
  128. Liu A.C. Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. American Journal of Pathology 2007;171:1407–1418.
  129. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. American Journal of Physiology 2009;296:H756–H764.
  130. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. American Journal of Pathology 2010;177:49–57.
  131. Heistad D.D., Wakisaka Y., Miller J., Chu Y., Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circulation Journal 2009;73:201–207.
  132. Liberman M., Bassi E., Martinatti M.K., Lario F.C., Wosniak J.J., Pomerantzeff P.M., Laurindo F.R. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arteriosclerosis, Thrombosis and Vascular Biology 2008;28:463–470.
  133. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., McDonald J.M., Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor runx2 by akt signaling. Journal of Biological Chemistry 2008;283:15319–15327.
  134. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Peña-Silva R., Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. Journal of the American College of Cardiology 2008;52:843–850.
  135. Kawaguchi H., Akune T., Yamaguchi M., Ohba S., Ogata N., Chung U.I., Kubota N., Terauchi Y., Kadowaki T., Nakamura K. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. Journal of Bone and Mineral Metabolism 2005;23:275–279.
  136. Yamashita A., Takada T., Nemoto K., Yamamoto G., Torii R. Transient suppression of PPARgamma directed es cells into an osteoblastic lineage. FEBS Letters 2006;580:4121–4125.
  137. Rajamannan N.M., Subramaniam M., Stock S.R., Stone N.J., Springett M., Ignatiev K.I., McConnell J.P., Singh R.J., Bonow R.O., Spelsberg T.C. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806–810.
  138. Soini Y., Salo T., Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Human Pathology 2003;34:756–763.
  139. Charest A., Pepin A., Shetty R., Cоtе С., Voisine Р., Dagenais F., Pibarot P., Mathieu Р. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 2006;92:1844–1849.
  140. Cagirci G., Cay S., Canga A., Karakurt O., Yazihan N., Kilic H., Topaloğlu S., Aras D., Demir A.D., Akdemir R. Association between plasma asymmetrical dimethylarginine activity and severity of aortic valve stenosis. Journal of Cardiovascular Medicine 2011;12:96–101.
  141. Ngo D.T., Heresztyn T., Mishra K., Marwick T.H., Horowitz J.D. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide 2007;16:197–201.
  142. Ozaki M., Kawashima S., Yamashita T., Hirase T., Namiki M., Inoue N., Hirata K., Yasui H., Sakurai H., Yoshida Y., Masada M., Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoe-deficient mice. Journal of Clinical Investigation 2002;110:331–340.
  143. Jensky N.E., Criqui M.H., Wright M.C., Criqui M.H., Wright M.C., Wassel C.L., Brody S.A., Allison M.A. Blood pressure and vascular calcification. Hypertension 2010;55:990–997.
  144. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005–1011.
  145. Helske S., Lindstedt K.A., Laine M., Mаyrаnpаа M., Werkkala K., Lommi J., Turto H., Kupari M., Kovanen P.T. Induction of local angiotensin II–producing systems in stenotic aortic valves. Journal of the American College of Cardiology 2004;44:1859–1866.
  146. Didion S.P., Kinzenbaw D.A., Schrader L.I., Chu Y., Faraci F.M. Endogenous interleukin-10 inhibits angiotensin II–induced vascular dysfunction. Hypertension 2009;54:619–624.
  147. Schrader L.I., Kinzenbaw D.A., Johnson A.W., Faraci F.M., Didion S.P. Il-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arteriosclerosis, Thrombosis and Vascular Biology 2007;27:2576–2581.
  148. Arishiro K., Hoshiga M., Negoro N., Jin D., Takai S., Miyazaki M., Ishihara T., Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. Journal of the American College of Cardiology 2007;49:1482–1489.
  149. Yamamoto K., Yamamoto H., Yoshida K., Kisanuki A., Hirano Y., Ohte N., Akasaka T., Takeuchi M., Nakatani S., Ohtani T., Sozu T., Masuyama T. Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese aortic stenosis study (JASS) retrospective analysis. Hypertension Research 2010;33:269–274.
  150. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 1998;97:2433–2444.
  151. Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M., Schoen F.J. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: Implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006;113:1344–1352.
  152. Sukhova G.K., Zhang Y., Pan J.H., Wada Y., Yamamoto T., Naito M., Kodama T., Tsimikas S., Witztum J.L., Lu M.L., Sakara Y., Chin M.T., Libby P., Shi G.P. Deficiency of cathepsin s reduces atherosclerosis in ldl receptor-deficient mice. Journal of Clinical Investigation 2003;111:897–906.
  153. Edep M.E., Shirani J., Wolf P., Brown D.L. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovascular Pathology 2000;9:281–286.
  154. Fondard O., Detaint D., Iung B., Choqueux C., Adle-Biassette H., Jarraya M., Hvass U., Couetil J.P., Henin D., Michel J.B., Vahanian A., Jacob M.P. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. European Heart Journal 2005;26:1333–1341.
  155. Helske S., Syvaranta S., Kupari M., Lappalainen J., Laine M., Lommi J., Turto H., Mаyrаnpаа M., Werkkala K., Kovanen P.T., Lindstedt K.A. Possible role for mast cell-derived cathepsin g in the adverse remodelling of stenotic aortic valves. European Heart Journal 2006;27:1495–1504.
  156. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circulation Research 2003;92:827–839.
  157. Aikawa E., Aikawa M., Libby P., Figueiredo J.L., Rusanescu G., Iwamoto Y., Fukuda D., Kohler R.H., Shi G.P., Jaffer F.A., Weissleder R. Arterial and aortic valve calcification abolished by elastolytic cathepsin s deficiency in chronic renal disease. Circulation 2009;119:1785–1794.
  158. Simionescu A., Simionescu D.T., Vyavahare N.R. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: Role of myofibroblasts in vascular calcification. American Journal of Pathology 2007;171:116–123.
  159. Qin X., Corriere M.A., Matrisian L.M., Guzman R.J. Matrix metalloproteinase inhibition attenuates aortic calcification. Arteriosclerosis, Thrombosis and Vascular Biology 2006;26:1510–1516.
  160. Karnik S.K., Brooke B.S., Bayes-Genis A., Sorensen L., Wythe J.D., Schwartz R.S., Keating M.T., Li D.Y. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003;130:411–423.
  161. Lai C.F., Seshadri V., Huang K., Shao J.S., Cai J., Vattikuti R., Schumacher A., Loewy A.P., Denhardt D.T., Rittling S.R., Towler D.A.K. An osteopontin-nadph oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circulation Research 2006;98:1479–1489.


Об авторах / Для корреспонденции

Сведения об авторах:
ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, Кемерово
Барбараш О.Л. - д.м.н., проф., директор Института.
Лаборатория кардиоваскулярного биопротезирования
Рутковская Н.В. - к.м.н., ст.н.с.
E-mail: astasev@gmail.com

К содержанию номера

Бионика Медиа   Apple Store